Recent News

INT230-6 Granted Fast Track Designation in Metastatic Triple-Negative Breast Cancer

AACR 2019: Primary Tumor Surgery for Advanced HER2-Positive Breast Cancer

AACR 2019: Predicting Breast Cancer Survival With Estrogen Byproducts

HOPA 2019: Does Receptor Expression Affect Efficacy of Talazoparib in Advanced Breast Cancer?

Is There a Link Between Age Acceleration and Breast Cancer Risk?

FDA Extends Indication of Palbociclib Combination to Men With Breast Cancer

Novel Antibody Drug-Conjugate in Metastatic Triple-Negative Breast Cancer

Study Finds Shifting Trend in Breast Cancer Risk in Asian American Women

Predicting Outcomes With Lung Immune Prognostic Index

ASCO-SITC 2019: HER2-Targeted Vaccine Plus Trastuzumab in Breast Cancer

Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer Approved by the FDA

FDA Grants Accelerated Approval to Atezolizumab Combination in Triple-Negative Breast Cancer

FDA Approves New Formulation of Trastuzumab for Subcutaneous Use in Some Breast Cancers

2019 ASCO-SITC: Neoadjuvant Chemotherapy and the Immunologic Landscape in Breast Cancer

Targeting Chemotherapy-Resistant Breast Cancer

Can Oolong Tea Inhibit Growth of Breast Cancer?

Reducing Risk for Invasive Breast Cancer With Low-Dose Tamoxifen

Comparing Breast Irradiation Regimens in Preventing Local Recurrence

Impact of Pathologic Complete Response on Breast Cancer Recurrence and Mortality

Racial Disparities in Breast Cancer Prevention: Focus on Complexity of Gathering Information

FDA Approves Trastuzumab Biosimilar for Treatment of Advanced Breast Cancer

Predictive Biomarker in Metastatic Triple-Negative Breast Cancer

Does Oxybutynin Reduce Hot Flashes in Breast Cancer Survivors?

SOLAR-1: Predicting Response to Alpelisib in PIK3CA-Mutant Breast Cancer

Can Cryoablation ‘Freeze Out’ Low-Risk Breast Cancers?

Shedding Light on Resistance to PARP Inhibitors in Patients With Breast Cancer

Conventional Whole-Breast vs. Partial-Breast Irradiation in Controlling Tumor Recurrence

Should Some Women Younger Than Age 30 Undergo Mammography?

SABCS 2018: Adjuvant Capecitabine for Early-Stage Triple-Negative Breast Cancer

SABCS 2018: Adjuvant Therapies for HER2-Positive Breast Cancer Compared in KATHERINE Trial

FDA Approves Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer

SABCS 2018: Comparing Letrozole With and Without Palbociclib in Metastatic Breast Cancer

Risk Class May Be Linked to Response to Breast Cancer Treatments

SABCS 2018: Novel Tool for Assessing Risk of Chemotherapy Toxicity in Older Patients With Breast Cancer

Rethinking Screening Mammography in Women Aged 75 and Older

SABCS 2018: Duration of Adjuvant Trastuzumab in Early Breast Cancer

SABCS 2018: When to Initiate Adjuvant Chemotherapy in Triple-Negative Breast Cancer

Shorter Course of Trastuzumab in Some HER2-Positive Early Breast Cancers

Machine-Learning Prognostic Risk Model for African American Women With Breast Cancer

Endocrine Therapy on Trial in Male Breast Cancer

HDAC Inhibitor Studied in Treatment of Advanced Breast Cancer

City of Hope Launches CAR T-Cell Trial in Patients With Breast Cancer and Brain Metastases

ESMO 2018: Zoledronic Acid and Letrozole vs. Tamoxifen in Early Breast Cancer

FDA Grants Priority Review to Atezolizumab Plus Chemotherapy in Triple-Negative Breast Cancer

ESMO 2018: Targeting the Tumor Genome in Advanced Breast Cancer

ASTRO 2018: Radiation After Surgery for Low-Risk Ductal Carcinoma in Situ

ESMO 2018: Novel Combination Therapy for Advanced Breast Cancer

Novel Regional Anesthesia Technique for Pain Management After Mastectomy

ASTRO 2018: Long-Term Effects of Once-Weekly vs. Conventional Breast Radiation

Active Monitoring for Low-Risk Ductal Carcinoma in Situ

ESMO 2018: Atezolizumab Plus Nab-Paclitaxel in Metastatic Triple-Negative Breast Cancer